Kessiah Abaniel serves as the Vice President of Business Development at GeneHarmonics Inc., where she plays a pivotal role in advancing the company's mission to revolutionize biotechnology research and development. With a robust background in both B2B and B2C sales and contracting, Kessiah has honed...
Kessiah Abaniel serves as the Vice President of Business Development at GeneHarmonics Inc., where she plays a pivotal role in advancing the company's mission to revolutionize biotechnology research and development. With a robust background in both B2B and B2C sales and contracting, Kessiah has honed her expertise in the technology, healthcare, and design sectors over the past decade. Her leadership in go-to-market (GTM) strategies and product development for AI-driven solutions has been instrumental in generating over $5 billion in revenue, showcasing her ability to drive significant business growth.
At GeneHarmonics, Kessiah is currently spearheading key projects that focus on enhancing the health and wellness ecosystem globally. One of her primary initiatives involves recruiting and providing quality clinical staff from international markets to the United States, ensuring that healthcare providers have access to the best talent available. Additionally, she is deeply involved in the development of innovative biotechnology devices that promise to transform the landscape of healthcare delivery. Her strategic vision and commitment to excellence are reflected in her ability to foster partnerships and collaborations that align with the company's goals.
Kessiah's skill set is diverse, encompassing nursing, media relations, and data analysis, which she leverages to mentor her team and drive executive management initiatives. Her strong presentation skills and leadership capabilities enable her to effectively communicate complex ideas and inspire her team to achieve ambitious objectives. As a passionate advocate for advancing biotechnology, Kessiah Abaniel is not only shaping the future of GeneHarmonics but also contributing to the broader evolution of the healthcare industry.
